LOGO
LOGO

Article Search

Discover the power of RTTNews website's advanced search page, designed for seamless Article retrieval by Company Name, Stock Symbol, and other criteria.
Stay updated with the Latest News on specific Companies, Financial Insights, and Market Trends. We Ensure you to get the most relevant information instantly.

Symbol  
Company  
Currency Symbol   eg (EUR/USD)
Keyword  
  • IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/1/2024 6:04:11 AM
  • Wedbush Reiterates IDEAYA Biosciences (IDYA) At Outperform With $52 Price Target 10/28/2024 10:16:09 AM
  • IDEAYA Biosciences Announces IND-Clearance For IDE275 (GSK959) For Phase 1 Study In MSI-High Solid Tumors 10/28/2024 6:11:27 AM
  • IDEAYA Presents Positive Phase 1 Expansion Data Of IDE397 In MTAP-Deletion Urothelial&Lung Cancer At EORTC-NCI-AACR 2024 10/25/2024 6:05:28 AM
  • IDEAYA Biosciences Announces IDE397 Phase 1 Expansion Results 10/4/2024 6:08:24 AM
  • IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 9/27/2024 6:01:21 AM
  • IDEAYA Biosciences Announces Positive Interim Phase 2 Clinical Trial Data For Darovasertib In Neoadjuvant Uveal Melanoma 9/23/2024 6:04:40 AM
  • IDEAYA To Report Interim Phase 2 Data For Darovasertib And Regulatory Update From FDA Type C Meeting On Sept 23 9/22/2024 9:17:57 AM
  • IDEAYA Biosciences Appoints Douglas Snyder As SVP, General Counsel 9/18/2024 6:01:45 AM
  • IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8/23/2024 6:01:24 AM
  • Wedbush Is Cutting IDEAYA Biosciences (IDYA) FY25 Estimate To -3.49 From -3.14 8/7/2024 12:12:55 PM
  • Wedbush Is Cutting IDEAYA Biosciences (IDYA) Q4 25 Estimate To -0.96 From -0.83 8/7/2024 12:12:39 PM
  • Wedbush Is Lowering IDEAYA Biosciences (IDYA) Q3 25 Estimate To -0.90 From -0.82 8/7/2024 12:12:26 PM
  • Wedbush Is Lowering IDEAYA Biosciences (IDYA) Q2 25 Estimate To -0.84 From -0.77 8/7/2024 12:12:11 PM
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap